UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Rapid phenotypic and genomic change in response to therapeutic pressure in prostate cancer inferred by high content analysis of single circulating tumor cells

PloS one, 2014-08, Vol.9 (8), p.e101777-e101777

2014

Volltextzugriff (PDF)

Impact of resistance training on body composition and metabolic syndrome variables during androgen deprivation therapy for prostate cancer: a pilot randomized controlled trial

BMC cancer, 2018-04, Vol.18 (1), p.368-15, Article 368

2018

Volltextzugriff (PDF)

Detection of Androgen Receptor Mutations in Circulating Tumor Cells in Castration-Resistant Prostate Cancer

Clinical chemistry (Baltimore, Md.), 2010-09, Vol.56 (9), p.1492-1495

2010

Volltextzugriff (PDF)

Monitoring dynamic cytotoxic chemotherapy response in castration-resistant prostate cancer using plasma cell-free DNA (cfDNA)

BMC research notes, 2019-05, Vol.12 (1), p.275-275, Article 275

2019

Volltextzugriff (PDF)

Automated analysis of co-localized protein expression in histologic sections of prostate cancer

PloS one, 2017-05, Vol.12 (5), p.e0178362-e0178362

2017

Volltextzugriff (PDF)

Prospective evaluation of 18F-NaF and 18F-FDG PET/CT in detection of occult metastatic disease in biochemical recurrence of prostate cancer

Clinical nuclear medicine, 2012-07, Vol.37 (7), p.637-643

2012

Volltextzugriff (PDF)

Expression and functional role of orphan receptor GPR158 in prostate cancer growth and progression

PloS one, 2015-02, Vol.10 (2), p.e0117758

2015

Volltextzugriff (PDF)

Effect of Periodized Resistance Training on Skeletal Muscle During Androgen Deprivation Therapy for Prostate Cancer: A Pilot Randomized Trial

Integrative cancer therapies, 2021, Vol.20, p.15347354211035442-15347354211035442

2021

Volltextzugriff (PDF)

Immune biomarkers associated with COVID-19 disease severity in an urban, hospitalized population

Practical laboratory medicine, 2023-08, Vol.36, p.e00323-e00323, Article e00323

2023

Volltextzugriff (PDF)

Cell State and Cell Type: Deconvoluting Circulating Tumor Cell Populations in Liquid Biopsies by Multi-Omics

Cancers, 2023-08, Vol.15 (15), p.3949

2023

Volltextzugriff (PDF)

Effect of Monoamine oxidase A (MAOA) inhibitors on androgen‐sensitive and castration‐resistant prostate cancer cells

The Prostate, 2019-05, Vol.79 (6), p.667-677

2019

Volltextzugriff (PDF)

CCR2-targeted micelles for anti-cancer peptide delivery and immune stimulation

Journal of controlled release, 2021-01, Vol.329, p.614-623

2021

Volltextzugriff (PDF)

Focal Cryotherapy for Clinically Unilateral, Low-Intermediate Risk Prostate Cancer in 73 Men with a Median Follow-Up of 3.7 Years

European urology, 2012-07, Vol.62 (1), p.55-63

2012

Volltextzugriff (PDF)

Blood-based gene expression profiling in castrate-resistant prostate cancer

BMC medicine, 2015-09, Vol.13 (1), p.219-219, Article 219

Gross, Mitchell E

2015

Volltextzugriff (PDF)

Synthesis and anti-cancer potential of potent peripheral MAOA inhibitors designed to limit blood:brain penetration

Bioorganic & medicinal chemistry, 2023-09, Vol.92, p.117425-117425, Article 117425

2023

Volltextzugriff (PDF)

Loss of ER retention motif of AGR2 can impact mTORC signaling and promote cancer metastasis

Oncogene, 2019-04, Vol.38 (16), p.3003-3018

2019

Volltextzugriff (PDF)

Androgen receptor in cancer-associated fibroblasts influences stemness in cancer cells

Endocrine-related cancer, 2017-04, Vol.24 (4), p.157-170

2017

Volltextzugriff (PDF)

Phase 2 trial of monoamine oxidase inhibitor phenelzine in biochemical recurrent prostate cancer

Prostate cancer and prostatic diseases, 2021-03, Vol.24 (1), p.61-68

2021

Volltextzugriff (PDF)

Intolerance of uncertainty, cognitive complaints, and cancer-related distress in prostate cancer survivors

Psycho-oncology (Chichester, England), 2015-02, Vol.24 (2), p.228-235

2015

Volltextzugriff (PDF)

Anterior gradient 2 (AGR2): Blood-based biomarker elevated in metastatic prostate cancer associated with the neuroendocrine phenotype

The Prostate, 2013-02, Vol.73 (3), p.306-315

2013

Volltextzugriff (PDF)

Prostate cancer: Age is nothing but a number

Nature reviews. Urology, 2013-12, Vol.10 (12), p.683

Gross, Mitchell E

2013

Volltextzugriff (PDF)

Once-daily Dasatinib: Expansion of Phase II Study Evaluating Safety and Efficacy of Dasatinib in Patients With Metastatic Castration-resistant Prostate Cancer

Urology (Ridgewood, N.J.), 2011-05, Vol.77 (5), p.1166-1171

2011

Volltextzugriff (PDF)

Phase I/II Trial of Orteronel (TAK-700)―an Investigational 17,20-Lyase Inhibitor―in Patients with Metastatic Castration-Resistant Prostate Cancer

Clinical cancer research, 2014-03, Vol.20 (5), p.1335-1344

2014

Volltextzugriff (PDF)

Age is nothing but a number

Nature reviews. Urology, 2013-12, Vol.10 (12), p.683-684

Gross, Mitchell E.

2013

Volltextzugriff (PDF)

1 – 25 von 178

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(160)
Mit Volltextzugriff
(143)

Publikationsform

Sprache

Englisch
(177)
Japanisch
(19)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(2)
... seit 90 Tagen
(5)

Menü

Weitere Dienste

Einstellungen

Rapid phenotypic and genomic change in response to therapeutic pressure in prostate cancer inferred by high content analysis of single circulating tumor cells

Impact of resistance training on body composition and metabolic syndrome variables during androgen deprivation therapy for prostate cancer: a pilot randomized controlled trial

Detection of Androgen Receptor Mutations in Circulating Tumor Cells in Castration-Resistant Prostate Cancer

Monitoring dynamic cytotoxic chemotherapy response in castration-resistant prostate cancer using plasma cell-free DNA (cfDNA)

Automated analysis of co-localized protein expression in histologic sections of prostate cancer

Prospective evaluation of 18F-NaF and 18F-FDG PET/CT in detection of occult metastatic disease in biochemical recurrence of prostate cancer

Expression and functional role of orphan receptor GPR158 in prostate cancer growth and progression

Effect of Periodized Resistance Training on Skeletal Muscle During Androgen Deprivation Therapy for Prostate Cancer: A Pilot Randomized Trial

Immune biomarkers associated with COVID-19 disease severity in an urban, hospitalized population

Cell State and Cell Type: Deconvoluting Circulating Tumor Cell Populations in Liquid Biopsies by Multi-Omics

Effect of Monoamine oxidase A (MAOA) inhibitors on androgen‐sensitive and castration‐resistant prostate cancer cells

CCR2-targeted micelles for anti-cancer peptide delivery and immune stimulation

Focal Cryotherapy for Clinically Unilateral, Low-Intermediate Risk Prostate Cancer in 73 Men with a Median Follow-Up of 3.7 Years

Salvage ablative therapy in prostate cancer: International multidisciplinary consensus on trial design

Blood-based gene expression profiling in castrate-resistant prostate cancer

Synthesis and anti-cancer potential of potent peripheral MAOA inhibitors designed to limit blood:brain penetration

Loss of ER retention motif of AGR2 can impact mTORC signaling and promote cancer metastasis

Androgen receptor in cancer-associated fibroblasts influences stemness in cancer cells

Phase 2 trial of monoamine oxidase inhibitor phenelzine in biochemical recurrent prostate cancer

Intolerance of uncertainty, cognitive complaints, and cancer-related distress in prostate cancer survivors

Anterior gradient 2 (AGR2): Blood-based biomarker elevated in metastatic prostate cancer associated with the neuroendocrine phenotype

Prostate cancer: Age is nothing but a number

Once-daily Dasatinib: Expansion of Phase II Study Evaluating Safety and Efficacy of Dasatinib in Patients With Metastatic Castration-resistant Prostate Cancer

Phase I/II Trial of Orteronel (TAK-700)―an Investigational 17,20-Lyase Inhibitor―in Patients with Metastatic Castration-Resistant Prostate Cancer

Age is nothing but a number

Suchergebnisse filtern